From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

Like this article?

Get your free daily medical news from Physician's First Watch.

RSS

New Data Suggest Safety of Hormone Therapy in Early Menopause

In early menopause, 10 years of hormone therapy might lower the risk for cardiac events without raising the risk for cancer, thrombosis, or stroke, according to an open-label study in BMJ.

Roughly 1000 newly menopausal women (mean age, 50) in Denmark were randomized to hormone therapy (estradiol plus norethisterone acetate for those with an intact uterus, estradiol alone for those posthysterectomy) or to no treatment. The intervention was stopped at 10 years, after the Women's Health Initiative reported HT-associated harms.

At the end of treatment, the primary outcome — a composite of death, MI, or heart failure — was less common among women on HT; this significant benefit persisted through 16 years' total follow-up. Risks for thrombosis, stroke, and cancer did not differ between the groups. Speculating on why these results differ from the WHI's findings, the researchers point to the younger age of the current cohort and the different hormones used.

Andrew Kaunitz of Journal Watch Women's Health said: "Taken together with findings from a subanalysis of younger women from the WHI, these data should reassure clinicians and women that use of hormone therapy in recently menopausal women is safe."

LINK(S):

BMJ article (Free)

Background: Physician's First Watch coverage of recent study on short-term HT for early menopausal symptoms (Free)

Background: Journal Watch Women's Health summary on subanalysis of younger WHI participants (Your Journal Watch registration required)

Published in Physician's First Watch October 10, 2012

Reader Remarks:

Review and add to remarks on this article

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

The editors of Journal Watch may respond to Reader Remarks, but we cannot promise to respond to a particular remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Sign-In

Forgot your password? Login via Athens
or your institution

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2012. Massachusetts Medical Society. All rights reserved.